HIV

Data from the CALIBRATE and CAPELLA trials show high rates of virologic suppression with the capsid inhibitor.

Through the 240 weeks, numerically small median changes in eGFR and stable TC:HDL ratios were observed in both studies.

The use of a unique trimer to produce tier-2 neutralizing antibodies may help fight HIV.

Effective pre-exposure prophylaxis limits the additional price that payers should be willing to pay for the pre-exposure prophylaxis, investigators say.

Although COVID-19 vaccination rates have increased since the survey was initially conducted, the researchers noted that their results are important when considering the possibility of an annual COVID-19 vaccine.

Medication can now be used as few as 6 times a year for virologically suppressed adults living with the disease without prior treatments not working or resistance to cabotegravir or rilpivirine.

The analysis of 204 countries and territories reveals that AMR is now a leading cause of death worldwide, which is higher than HIV/AIDS or malaria.

These findings suggest people with indications for PrEP may confront an access barrier if they live in a state that restricts scope of practice, according to the study.

Fostemsavir (Rukobia) is indicated in combination with other antiretroviral medications in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection.

Cabotegravir (Apretude) is indicated for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection.

When left untreated, this gut condition an inflamed can accelerate arterial disease, which can lead to a heart attack or stroke, according to research from UCLA.

Study results show that these regimens increased the chances of treatment success among individuals aged 3 to 18 years compared to standard therapeutics.

The findings showed that people with HIV were 68% more likely to develop heart failure than people who did not have HIV.

Cabenuva (Cabotegravir-rilpivirine) is a 2-drug co-packaged product indicated as a complete regimen for the treatment of HIV-1 infection in adults.

Immunocompromised individuals are at a higher risk of developing severe symptoms and dying from COVID-19.

The long-acting antiretroviral therapy is intended to replace antiretroviral regimens for individuals who are virologically suppressed.

In this video, Dr. Sherman recommends strategies for solving drug therapy related problems common to long-acting antiretroviral agents, such as missed doses, adverse drug reactions and drug–drug interactions.

In this video, Dr. Sherman explains the recent data surrounding the right candidates for long-acting cabotegravir for HIV prevention.

In this video, Dr. Sherman describes the pharmacology and pharmacokinetics of cabotegravir and rilpivirine as long acting injectable antiretroviral therapy agents.

In this video, Dr. Sherman describes what pre-exposure prophylaxis is and how long-acting injectable antiretroviral agents can help to prevent HIV and may even improve adherence.

Marinol is a cannabinoid indicated for anorexia associated with weight loss in patients with AIDS.

The data included more than 21,500 children and adolescents 17 years of age and younger with HIV and more than 255,000 adults with HIV, all of whom began receiving ART between 2010 and 2019.

Ten quiz questions to assess your knowledge on common symptoms and treatments for HIV.

Juluca is indicated as a complete regimen for the treatment of HIV-1 infection in adults.

Receipt of PrEP education or prescription relies heavily on a provider’s discretion, which can be subject to social biases.

The study also collected patient-reported outcomes in routine clinical practice to understand the impact of treatment on health-related quality of life.

The success of the COVID-19 messenger RNA (mRNA) vaccines from Pfizer/BioNTech and Moderna has given many HIV advocates hope that a preventive mRNA vaccine is on the horizon.

Phase 3 ILLUMINATE showed the percentage of individuals with HIV-1 RNA levels ≥50 copies/mL for the once-a-day combination pill of doravirine/islatravir.

After switching to Biktarvy, 91% of patients remained virologically suppressed at week 24 in a cohort study.

The authors said stigmatization threatens societal cohesion during times of national upheaval, such as during a pandemic.